Morphine: The God of Dreams

A 20-year-old at a pharmacy bench

In 1803, a German apprentice pharmacist named Friedrich Sertürner — 20 years old, untrained as a scientist, working at an apothecary in Paderborn — began trying to figure out what, exactly, was in opium.

Opium had been used medicinally for at least 5,000 years. Sumerian tablets called the opium poppy hul gil, “joy plant.” Egyptian physicians prescribed it. Greek doctors gave it for pain, cough, and diarrhea. By Sertürner’s time, every European doctor carried tincture of opium — laudanum — and prescribed it freely. People drank it for headaches, for menstrual cramps, to settle infants.

But nobody knew which of opium’s many compounds did the work. Doses were impossible to standardize. The same “ten drops of laudanum” might do nothing to one patient and kill another. Sertürner’s question was direct: what is the active substance?

The chemistry of plant compounds was, in 1803, essentially unexplored. Sertürner had no training, no funding, no mentor. He had a pharmacy bench and an extraordinary level of patience. Over several years of crude extraction — boiling opium in water, treating with ammonia, filtering, recrystallizing — he isolated a white crystalline substance that he called principium somniferum, the “sleep-bringing principle.”

It was the first pure alkaloid ever isolated from a plant. Before Sertürner, every “drug” was a crude plant extract whose active ingredients were unknown. After Sertürner, chemistry could begin to identify what specifically did what.

He tested it on himself first, then on three young friends in 1805. The dose was much higher than he’d intended; all three nearly died. He published the results anyway. Eventually the French chemist Joseph Louis Gay-Lussac suggested a better name based on Greek myth: morphine, after Morpheus, the god of dreams.

The 20-year-old apothecary’s apprentice had given the modern pharmaceutical industry its starting molecule.

What this single discovery began

The 19th century became the age of alkaloids directly because of Sertürner. Within decades, chemists had pulled quinine from cinchona bark (1820), caffeine from coffee (1819, by Runge), nicotine from tobacco (1828), atropine from belladonna (1833), codeine from opium (1832), cocaine from coca (1860). Every one of these followed Sertürner’s method.

Each alkaloid was, in its time, a revolution. Pure caffeine made coffee dose-controllable. Pure quinine made malaria treatable. Pure cocaine became the first effective local anesthetic. Pure morphine became the first dose-standardizable analgesic; for the first time in human history, a doctor could give a patient an exact gram of pain relief and know what would happen.

By the 1850s, the hypodermic syringe had been invented by Alexander Wood in Edinburgh. (A long-repeated story claims Wood’s wife was the first IV morphine addict, dying of overdose — it’s apocryphal: she outlived her husband by a decade.) Whatever the personal stories, the combination of pure morphine + IV injection was a new technology with consequences nobody had calculated.

The American Civil War in the 1860s gave morphine to about 400,000 wounded Union and Confederate soldiers. Tens of thousands came home addicted. The condition was called soldiers’ disease. It was the first time a modern army had created its own opioid epidemic.

What it does, in 2 minutes

Morphine (C₁₇H₁₉NO₃) is a small molecule by drug standards — 17 carbons, with the characteristic phenanthrene ring system shared by all natural opioids. Its three-dimensional shape happens to fit, almost perfectly, into a protein in your brain and spinal cord called the μ-opioid receptor (mu-opioid).

The μ-opioid receptor exists in you because your body makes its own opioids: endorphins (released during exercise, sex, childbirth, injury) and enkephalins (released during stress and pain). These are short peptide chains your nervous system uses to dial down pain signaling. When you “rub it better” or “walk it off,” you’re activating endorphin release.

Morphine binds these receptors at higher affinity than your natural ligands. When it binds, three things happen quickly. First, pain signals from your body to your brain are blocked at the spinal cord — the messages literally don’t get through. Second, the emotional component of pain — the suffering layer added by your limbic system — is muted; patients on morphine often report “the pain is still there, but it doesn’t bother me.” Third, the brain’s pleasure circuitry (the same ventral tegmental area dopamine pathway involved in addiction) is activated. Most people experience this as a deep, warm calm.

The pain relief is profound. The euphoria is dangerous. The combination is, depending on context, a miracle or a trap.

A note on the second story of pain

Pain, neurobiologically, is two systems. The first is the sensory-discriminative system: nerve signals from your tissues telling your brain where it hurts, how much, what kind. The second is the affective-motivational system: the part of pain that bothers you and motivates you to avoid it.

Morphine, and all μ-agonists, blunt the second system far more than the first. This is the molecular basis of the patient quote that haunts every palliative care conversation: “I’m still in pain, but I don’t care.” The hippocampus knows there’s tissue damage. The anterior cingulate cortex no longer cares.

This is why morphine remains, two hundred years after Sertürner, the gold standard for cancer pain, post-surgical pain, and end-of-life care. Nothing else humans have synthesized matches its specific combination of analgesia, sedation, and emotional cushioning.

The bayer side

A small chemical modification — acetylation of morphine’s two hydroxyl groups — produces a derivative that crosses the blood-brain barrier two to four times faster than morphine itself. In the brain, esterases hydrolyze it back to (mono-acetylated and then) plain morphine. The effect is a more rapid, more intense onset for the same eventual dose.

That compound is diacetylmorphine. Trade name when Bayer commercialized it in 1898: Heroin. The name was supposed to evoke heroisch — heroic, courageous — and was originally marketed as a non-addictive cough remedy and a treatment for morphine addiction. It was sold over the counter at drugstores. Aspirin and heroin were on Bayer’s price list in the same column.

The discovery that heroin was more, not less, addictive than morphine took about ten years. Bayer stopped manufacturing it in 1913. It was scheduled in the US in 1924. The damage was already done — a generation of users had been created, and the supply chain had moved from pharmacies to organized crime, where it has stayed ever since.

This is the molecule’s defining pattern: every attempt to make a “safer” opioid has either failed (oxycodone was meant to be less addictive than morphine; it isn’t) or worked too well (fentanyl is 50–100× the potency of morphine, fits in a postal envelope, and now drives most US overdose deaths).

80,000 a year

The US is currently in the worst drug overdose epidemic in human history. Annual US drug overdose deaths total about 80,000; opioids — almost entirely synthetic descendants of Sertürner’s 1804 isolate — account for the large majority (roughly 55,000–80,000 depending on the year and how inclusively you count), with fentanyl driving most of the recent rise. For comparison, the entire Vietnam War killed about 58,000 Americans over twelve years.

The molecular reasons are now well understood. Opioid receptors, like dopamine receptors under chronic stimulation, downregulate. The user needs more drug to achieve the same effect (tolerance). When the user stops, the under-stimulated receptors produce withdrawal — diarrhea, vomiting, chills, intense muscle pain, suicidal hopelessness — that lasts about a week and is severe enough that almost no one quits without medical support.

The medical-support approach that genuinely works — medication-assisted treatment with methadone or buprenorphine — uses long-acting μ-opioid agonists themselves. The treatment is the same family of molecule that caused the disease, at controlled doses on a stable schedule. This is unintuitive but the outcomes data are unambiguous: it cuts overdose deaths by about 60% and keeps people alive long enough to rebuild their lives. The problem is that fewer than 20% of US patients with opioid use disorder receive it, mostly because of regulatory restrictions and stigma.

Sertürner could not have predicted this. He thought he was extracting a sleep aid. The technology of separating the active compound from the plant — which he invented — gave humanity, simultaneously, modern medicine and modern addiction.

The first patient

Morphine relieves pain in dying patients better than anything else we have. Almost everyone reading this will, at some point in their life, have a relative who is dying — and the relief of that relative’s pain will involve morphine or one of its close descendants. The doses given in hospice are titrated carefully but generously; the goal is comfort, not the avoidance of dependence (a dying patient cannot become “addicted” in any meaningful sense).

There is a specific medical phrase for the kind of pain morphine treats best: total pain. Coined by Dame Cicely Saunders, the founder of the modern hospice movement, the phrase refers to suffering that combines physical pain with psychological distress, spiritual anguish, and social isolation. Morphine relieves all four components, not just the first. This is the molecule at its truest.

Two hundred and twenty years ago, a 20-year-old apprentice pharmacist isolated a compound that, today, both kills 80,000 Americans a year and holds the hand of every cancer patient in the world in their last hours. No molecule before or since has carried that range of human good and harm in such an inseparable bundle.

That is the legacy of one careful, untrained pharmacist working alone with opium, ammonia, and a recrystallization dish, two centuries ago in Westphalia, who looked at the white crystals he had finally produced and named them after the god of dreams.

---

The morphine molecule has its own 3D page in the library — rotate it, see the phenanthrene scaffold that fits the μ-opioid receptor, download the structure file. It also has its own bouncing wallpaper.